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Abstract: Most critically ill patients exhibit a myriad of symptoms with irregular glycaemic regulation 
and renal failure contributing to a large proportion of mortality and morbidity. Hence, the effect of 
dialysis on glycaemic regulation should be of interest to clinicians as it is a common therapy addressing 
renal failure. 
In this investigation, we measure transient changes in model-based insulin sensitivity during the 
commencement and end of dialysis periods in 51 critically ill patients with acute renal failure (ARF). The 
clinically validated model-based insulin sensitivity (SI) metric is a lumped parameter, which, in this case, 
can account for variance in insulin pharmacokinetics and production, as well as the efficiency of insulin 
mediated glucose uptake. Apparent SI is expected to be higher during renal failure as insulin will not be 
cleared as fast as the model assumed. Thus, it is hypothesized given model assumptions on steady, 
population levels of renal insulin clearance, that dialysis will cause a drop in model-based SI, and vice 
versa. This study is the first to investigate the effect of dialysis on insulin action of critically ill patients. 
This investigation found a significant reduction in model-based SI after the commencement of dialysis, 
but an insignificant change when dialysis was stopped. As dialysis was considered to have little effect on 
true insulin sensitivity and the effect on insulin production would have been contrary to the observed 
behavior, it was concluded that commencing dialysis had a significant effect in increasing insulin 
clearance over the cohort. This effect was not reciprocated immediately following dialysis due to a 
slower return to complete renal failure following treatment. 
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1. INTRODUCTION 
Acute renal failure (ARF) is a common complication for 
critically ill patients. Approximately 36% of critically ill 
patients are diagnosed with ARF (De Mendonca et al., 2000, 
Uchino et al., 2005, Metnitz et al., 2002). ARF can cause 
costly morbidities, with a significant proportion of patients 
progressing to end-stage renal disease requiring dialysis 
(Star, 1998). Several epidemiological studies have shown an 
increase in morbidity and mortality following the 
development of ARF (Bentley, 2011). 
 
The increasing incidence of ICU-related ARF may be 
explained by several factors, including a rising incidence of 
sepsis (Bagshaw et al., 2007), major surgery (especially 
cardiothoracic), nephrotoxic medications, and chronic 
medical conditions (history of chronic disease, congestive 
heart failure, and diabetes mellitus) (Hoste et al., 2003). In 
critically ill patients with renal failure, both uremia and 
dialysis can complicate glycaemic control by affecting 
secretion, insulin clearance, gluconeogenesis (Van Den 
Berghe et al., 2001), and peripheral tissue sensitivity of 
insulin (Shrishrimal et al., 2009). Hence, the time course of 
the important renal failure on metabolic behaviour in the 
critically ill is unknown. 
 
However, the net effect of haemodialysis on glycaemic 
regulation and insulin sensitivity in a critically ill cohort is 
unknown. 
 
This study uses dense clinical data and a model-based 
analysis to observe changes in a clinically validated model-
based SI metric at haemodialysis transitions in a cohort of 
critically ill patients. Specifically, we hypothesized that 
model-based SI would fall during dialysis due to enhanced 
insulin clearance not seen in the model, and would thus rise 
when dialysis is stopped. These changes in SI would provide 
a unique view on insulin action in the population of critically 
ill patients with ARF. 
  
 
 
 
 
2. METHODS 
2.1  Study Cohort 
Blood glucose (G), nutrition and insulin (I) data from 51 
critically ill patients with ARF were used in this study. 
Haemodialysis (HD) with polysulfone (PS) dialyzer was 
adapted to these patients where they were part of the SPRINT 
(Chase et al., 2008) study. These patients were 
haemodialysed three times weekly for at least 4 hour sessions 
at Intensive Care Unit (ICU) in Christchurch Hospital, New 
Zealand.  
 
Study inclusion required a minimum of 5 hours of patient 
data before dialysis, followed by at least 6 hours of dialysis, 
and then at least 5 hours after dialysis. The clinical details of 
this cohort, including baseline variables, are summarized in 
Table 1.The APACHE III diagnosis for these patients can be 
divided into 5 main groups: Sepsis (19/51), Cardiovascular 
(10/51), Trauma (9/51), Diabetes (7/51), and Respiratory 
(6/51). Full details on the patient cohort and SPRINT study 
can be found in (Chase et al., 2008). 
 
Table 1. Patient Details Summary (median [IQR]) 
 
Group Gender 
M/F 
Age  
(years) 
APACHE II 
Score  
Non-diabetic 34/10 65 [46-73] 24 [19-28] 
Diabetic 5/2 73 [53-73] 34 [22-36] 
2.2  Identification of Model-Based SI 
Model-based SI is identified hourly by fitting G 
measurements with estimated endogenous insulin secretion 
using the ICING model (Lin et al., 2011). An integral-based 
method (Docherty et al., 2009) and clinical data are used to 
identify a patient-specific stepwise SI profile with 1-hour 
resolution. The model is defined: 
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where: G (mmol.L-1) denotes the glucose above an 
equilibrium level, I and Q are plasma and interstitial insulin, 
respectively (mU.L-1), exogenous insulin is uex (mU.min-1), nI 
(min-1) defines the diffusion constant of insulin between 
compartments, and nC (min-1) is the cellular insulin clearance 
rate from interstitium. Patient endogenous glucose removal 
and insulin sensitivity are pG (min-1) and SI (L.mU-1.min-1), 
respectively, glucose and insulin distribution volume are VG 
(L) and VI (L), Michaelis-Menten functions are used to 
portray saturations, with αI (L.mU-1) dictating the saturation 
of plasma insulin clearance, and αG (L.mU-1) for saturation of 
insulin-mediated glucose removal, nK (min-1) and nL (min-1) 
are the renal and hepatic insulin clearance rates, respectively, 
xL is the first pass hepatic clearance ratio. P1 and P2 (mmol) 
represent the glucose in the stomach and gut, respectively, P 
is the glucose appearance in plasma (mmol.min-1) from 
enteral and parenteral nutrition. The parameters d1 and d2 are 
used to describe the rate of glucose transport through the 
enteral route into the bloodstream. The rate of transport from 
P2 is limited to the maximal gut glucose flux, Pmax, and also 
D represents the glucose input from enteral infusion 
(mmol.min-1). The parenteral (intravenous) glucose input rate 
is represented as PN (mmol.min-1). The endogenous insulin 
production uen (mU.min-1) is defined: 
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where: umin  (mU.min-1) and umax (mU.min-1) are the 
minimum and maximum pancreatic secretion rate, while k1 
and k2 are defined by normal glucose tolerance (NGT), Type 
I diabetes mellitus (T1DM), and Type 2 diabetes mellitus 
(T2DM). 
 
Table 2. Parameters and kinetic values based on diabetic 
status 
 
Model parameter values 
pG 0.006 min-1
αG 0.0154 L.mU-1
EGP 1.16 mmol.min-1
CNS 0.3 mmol.min-1
VG 13.3 L 
nI 0.006 min-1
nC 0.006 min-1
nK 0.0542 min-1
nL 0. 1578 min-1
αI 0.0017 L.mU-1
VI 4.0 L 
xL 0.67  
d1 0.0347 min-1 
d2 0.0069 min-1
Pmax 6.11 mmol.min-1
umin 16.7 mU.min-1
umax 266.7 mU.min-1
 NGT 14.9  
k1 T2DM 4.9 mU.L.mmol-1.min-1 
 T1DM 0.0  
 NGT -49.9  
k2 T2DM -27.4 mU.min-1 
 T1DM 16.7  
 
 
 
 
Table 2 defines all parameter values used. Note that renal 
clearance is set for a relatively normal level equivalent to 
glomerular filtration rate (GFR). 
2.3  Data Analysis 
The proportional difference in model identified SI (ΔSI) was 
calculated as:  
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Blood glucose changes, ΔG were calculated in a similar 
manner to ΔSI to access any change in glycaemia that could 
affect results. 
This analysis uses a 2-hour moving average to reduce the 
effect of measurement error, noise, and the influence of 
transient effects caused by the cohort-constant assumption of 
these model terms. SI profiles are identified over periods 
starting 3 hours before a dialysis commencement until 4 
hours after the dialysis ends. This limit ensures full settling of 
patient responses after transitions. Results are illustrated via 
G (linear-linear) and SI (log-log) plots. The logarithm plot is 
applied to illustrate SI (10-4) distribution at the OFF/ON 
transition. Wilcoxon rank sum tests are used to measure the 
significance of any shift in SI over the cohort at each 
transition. 
 
3. RESULTS 
Figure 1 shows the distribution of G and SI before and during 
dialysis over the OFF/ON transition at the commencement of 
dialysis. Note G is stable, but SI is slightly biased. Figures 2 
and 3 show ΔSI over time for the OFF/ON and ON/OFF 
dialysis transitions, which clearly showing the shift in SI. 
Table 3 (left) summarizes ΔSI over the OFF/ON transition for 
the cohort. A decrease of SI was observed after dialysis. The 
change is significant (p ≤ 0.05) after t=1 hours indicating an 
almost immediate effect. ΔSI settled to a median reduction of 
-29% at t = 2 hours. There were a moderate number of 
confounders (ΔSI>0). This implies that the observation was 
obscured by patient variability or that the effect itself is not 
always observable. 
ΔSI after the ON/OFF dialysis transition are shown in Table 3 
(right). Median ΔSI was insignificant at this transition. Hence, 
the number of confounders was higher after the ON/OFF 
dialysis transition. 
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Figure 1. G (left) and SI (right) distribution over the OFF/ON dialysis transition between *t=-1 and 2 (N=51) 
Figure 2. ∆SI over OFF/ON dialysis transition. t=0 indicates
commencement of dialysis. 
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Figure 3. ∆SI over ON/OFF dialysis transition. t=0 indicates
completion of dialysis. 
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In both cases, G remained effectively constant with 
insignificant changes (p>0.61). Hence, the impact of insulin 
sensitivity changes at both transitions on glycaemia was 
quickly accounted for by the SPRINT glycaemic control 
protocol and there were no difference in glycaemia. Equally, 
there is no impact on the results due to change in glycaemia. 
 
4. DISCUSSION 
This study investigated changes in a clinically validated 
model-based SI metric at transitions onto and off 
haemodialysis in a critically ill cohort undergoing glycaemic 
control. Significant insulin sensitivity changes were observed 
at the OFF/ON dialysis transition (p<0.05). This analysis 
shows that model-based SI decreased over the initial 4-hours 
of haemodialysis and the change was almost immediate. This 
result potentially indicates that dialysis significantly affected 
plasma insulin levels as expected, which, in turn, dictates 
glucose metabolism.  
 
Glucose intolerance among critically ill patients with ARF 
occurred with significant inhibition of insulin secretion and a 
state of peripheral insulin resistance (Defronzo et al., 1978, 
Mak, 1995) in addition to insulin resistance from critical 
illness (Basi et al., 2005). Thus, a reduction of available 
insulin may cause hyperglycaemia to occur during the initial 
periods of dialysis if tight glycaemic control (TGC) is not 
concurrent. 
 
A tendency for inhibited insulin secretion has also been 
observed in patients with severely compromised renal 
function (Fliser et al., 1998). The effects of insulin resistance 
can be exacerbated by impairment of the role of insulin in 
maintaining the hepatic glucose balance (Defronzo et al., 
1981). Specifically, an inability of insulin to stimulate hepatic 
glucose uptake with decreasing insulin sensitivity was 
observed in acute renal failure patients (Valera Mora et al., 
2003). Thus, understanding the pharmacokinetics of insulin 
during dialysis is important clinically. 
 
ΔSI at the ON/OFF dialysis transition was insignificant. It is 
assumed that acute i.v. administration of 1,25-
dihydroxyvitamin D3, (1,25(OH)2D3 ) given to ARF patients 
during haemodialysis may increase insulin secretion and 
reverse glucose intolerance (Mak, 1995). An improvement in 
glucose metabolism was observed after a second study period 
by a lower mean glucose during dialysis and more rapid 
disappearance rate of glucose in the immediate post-dialysis 
period (Alfrey et al., 1967). Also, the glucose metabolism and 
renal function are expected to increase gradually in post-
dialysis compare with pre-dialysis when toxic substances that 
are suspected of hindering renal function are extracted. The 
insulin catabolism in patients with chronic uremia is 
reportedly reduced. This is mainly due to the lack of 
functioning renal tissue accompanied by toxic suppression of 
both insulin secretion and degradation, mitigated by dialysis 
(Navalesi et al., 1975). However, it has not been conclusively 
demonstrated that this might happen within the ARF patients 
undergoing haemodialysis in critical care. In addition, longer 
post-dialysis duration would likely show significant change 
in SI, but 10 to 15 hours of investigation post-dialysis would 
be impossible to segregate changes in SI from other issues and 
dysfunction of critical illness (Hampers et al., 1966). Thus, a 
substantial change in SI at OFF/ON transition indicates a 
continuous and fast process of cleaning and clearing waste 
substances from blood. However, at the ON/OFF transition, 
the recovery process to regulate and normalize blood is a lot 
slower physiologically. Hence, the model-based SI, after 
dialysis in this study may be expected to remain unchanged, 
as observed.  
 
Changes in G at the dialysis transitions were minimal 
indicating successful TGC was achieved with the SPRINT 
protocol (Chase et al., 2008). Almost no bias in ΔG was 
observed. Thus, the confounding factor plays no role. The 
outlier observed in Figure 1 with G≈10 mmol.L-1.suffered 
from cardiovascular disease and was identified as at risk of 
acute renal failure and diabetes Thus, this patient’s glucose 
control of was not fully realised in the timeframe presented 
here due to the complex interactions between these diseases 
(Sarnak et al., 2003).     
 
The model-based SI is an indication of overall glucose 
metabolism of critically ill patients and does not necessarily 
reflect the precise physiology of insulin. The changes in the 
model-based SI at a cohort level are unlikely to be caused in 
this case by actual variance in SI at cellular level. In 
particular, there is no apparent stimulus induced by 
haemodialysis to affect SI. ∆SI was most likely affected either 
by renal clearance changes or/and endogenous insulin 
secretion resulting in an increase in apparent SI in the model. 
 
The ICING model prediction of uen is made in terms of 
glucose concentration in the absence of direct measurement. 
Table 3. Summary of ΔSI at both haemodialysis transition, OFF/ON and ON/OFF, (N=51) 
Time 
*t 
OFF/ON ON/OFF 
Q1 Q2 Q3 p-value SI (↑) % Q1 Q2 Q3 p-value SI (↓) % 
-2 -7 1 10 0.9 (31/51) 61 -13 -4 3 0.7 (32/51) 63 
-1 0 0 0 1 (0/51) 0 0 0 0 1 (0/51) 0 
0 -24 -7 -1 0.3 (10/51) 20 -5 1 8 0.9 (24/51) 47 
1 -45 -14 -2 0.05 (7/51) 14 -7 2 15 0.9 (23/51) 45 
2 -58 -29 -6 0.02 (5/51) 10 -13 4 26 0.8 (21/51) 41 
3 -55 -19 -5 0.03 (9/51) 18 -15 9 28 0.7 (23/51) 45 
4 -46 -22 -5 0.03 (6/51) 12 -15 3 31 0.5 (24/51) 47 
*times are 2-hour averages rounded at the time shown, and dialysis transition between t=-1 and 0. Dialysis is started anytime between t=-1 
and t=0). Q1=25% percentile, Q2=50% percentile (median), Q3=75% percentile. 
a 
 
 
 
Hence, the effect of dialysis on uen may be poorly defined by 
the model. However, it has been shown that insulin also 
suppresses insulin production (Argoud et al., 1987, 
Liljenquist et al., 1978) . As plasma insulin concentration is 
suspected to decrease during dialysis, it may also be 
suspected that endogenous insulin production would be 
increasing, at a cohort level. This would actually increase the 
observed modelled SI over time, which is contrary to the 
observation. Hence uen dependence can be discounted as a 
potential reason for the shifts in modelled SI in this study. 
 
Overall, it would seem that the most likely contributor to the 
observed changes in SI was the rate of insulin clearance.  
SPRINT reduced mortality and morbidity rates among 
critically ill patients with tighter control than existing, more 
ad-hoc clinical approaches (Chase et al., 2008). There is still 
potential for improvement within this model-based TGC 
methodology. The effect of haemodialysis on plasma insulin 
and the mechanism of insulin clearance among critically ill 
patients with ARF were shown in this study to be a factor in 
governing SI, which drives model-based glycaemic control. 
However, further study must be undertaken to measure the 
effects of dialysis on the pharmacokinetics and dynamics 
relevant to glucose metabolism in the critically ill. A 
prospective cohort and clinical studies on critically ill 
patients with ARF may provide better context in 
understanding insulin kinetics during haemodialysis. 
Comparison from a different cohort with mixed levels of 
insulin resistance will also provide clearer effect of ΔSI, 
which may reveal further information in the underlying 
factors of specific insulin resistance. 
 
5.  CONCLUSION 
The findings of this study show distinct changes in model-
based insulin sensitivity during haemodialysis as an 
observable aspect of critically ill patient physiology. 
However, the precise pharmacokinetics/dynamics driving this 
change remain ambiguous. These results justify larger cohort 
investigation.  
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